Sarah Phillips Suehnholz
@SPSuehnholz
Followers
151
Following
567
Media
4
Statuses
72
Sr. Scientist @OncoKB @sloan_kettering
Joined January 2012
Join us May 31-June 4 at the ASCO 2024 Annual meeting in Chicago at Booth # 37106 to meet our team, explore our latest developments and learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB licensing and content!
0
4
7
Join us May 31-June 4 at the ASCO 2024 Annual meeting in Chicago at Booth # 37106 to meet our team, explore our latest developments and learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB licensing and content!
0
2
4
New OncoKB data release v4.16: Release of CDx page incl biomarker, cancer type, drug & specimen type. BRAF fusions & V600 mts L1 in LGG. ERBB2 amp L2 in salivary gland cancer & L3A in solid tumors, the latter following FDA-approval of T-DXd for HER2+ (IHC3+) tumors + 7 new genes
1
6
18
From the January issue— Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer, by @SPSuehnholz, @CDebyaniPhD et al. https://t.co/lQFP1IujVb
@OncoKB @MSKCancerCenter #PrecisionOncology
0
5
10
The OncoKB team will work to keep this Table up-to-date, so it can be a valuable resource for all in the Precision Oncology Field! Thanks to @HongxinZhang, @CDebyaniPhD, Calvin Lu and all involved!
0
0
1
For each drug, the table also lists the FDA-approved biomarker that is required for patient selection as well as the method of biomarker detection (ie. DNA/NGS-based detection, IHC etc.)
1
0
1
How do we define a Precision Oncology Therapy? Here you go, "A drug that is most effective in a molecularly defined subset of patients and for which pre-treatment molecular profiling is required for optimal patient selection"
1
0
1
It lists all FDA-approved drugs considered precision oncology therapies by @OncoKB and further classifies them as either: 1. first-in-class, 2. mechanistically- distinct, 3. follow-on or 3. resistance-based therapies
1
0
1
It complements our recent publication in @AACR_CD, Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer ( https://t.co/MhbvbCJMYR)! Check out Supp. Table 2!
1
1
2
Check out @OncoKB 's new Precision Oncology Therapies page ( https://t.co/EriudIextU)! It's a great resource publically accessible on the OncoKB website, and here's why....
oncokb.org
OncoKB™ is a precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that contains biological and clinical information about genomic alterations in cancer.
2
7
19
Check out our 2nd @OncoKB paper https://t.co/aQOFeN76db Since 1998, 43% of all oncology drugs are precision oncology drugs=biomarker testing req'd for tx eligibility From 2017-2022:~4X ⏫ in std care actionability based on mut found in a pt solid tumor cohort Tweetorial next..
0
13
29
People - I know it’s the last day of #AACR23 - but finish it w/ bang! Visit our Senior Scientist @MoriahNi_Phd in Section 13 (West side) poster #18 to see our @OncoKB poster & here about the latest developments we’re working on.
Please come see @MoriahNi_Phd present our OncoKB poster at #AACR23: Poster #6585, with a detailed overview of all OncoKB content and precision oncology features, as well as future plans.
0
6
23
GAME CHANGING @OncoKB release just in time for #AACR23! Introducing pages w/ the clinical implications of a mutation found in specific cancers & incl descriptions of the trial data underpinning level assignments (eg ALK fusions in IMT): https://t.co/u5NeMLrc1r You're welcome!
0
9
33
@OncoKB release people & >700 cancer genes curated to date! What a great way to join our team @OncoKB scientists @AmandaDhanes & @NicoleCFern!! 👏 @ritikakundra10 too! Also stay tuned for @OncoKB releases w/every new FDA targeted drug approval or NCCN precision oncology update!
0
2
13
New @OncoKB release people! 7 yrs post @DHymanMD & @baselga1's BRAF V600E basket trial, BRAF V600E is now Level 1 in all solid tumors ➡️ 4th @US_FDA recognized tumor agnostic biomarker after NTRK fusions, MSI-H & TMB-H Another 1st? ERBB2 oncogenic mut are Level 1 in #lungcancer
0
19
53
Great opportunity to work in the field of precision medicine with a wonderful team of scientists at one of the top cancer hospitals!
New cancer bio MA/PhD grad? Interested in #PrecisionMedicine? Want to grow & learn w/ a small diverse team in a startup/academia environment to make a cancer patient's journey easier? We're hiring @OncoKB people! APPLY https://t.co/vTGTGcMYfu
@BlackinCancer #WomenInSTEM @The_LCI
0
0
0
New @OncoKB release people! -KMT2A fusions & NPM1 mut level 3A based on compelling clinical activity of menin inh in pts w/ AML -ALK fusions are FINALLY level 1 in inflammatory myofibroblastic tumors! [PS. We're hiring! https://t.co/CKAB7opuNG]
0
7
28
Learn from literally the BEST in cancer biology informatics👇🏽 As a cancer researcher if you haven’t taken a look @cbioportal - do so NOW. If you don’t understand it, watch their webinars. Incredibly important tool to get familiar with. Also go to @ritikakundra10 #AACR22 talk!!
Work on Open Source Software for a summer and support Cancer Research! Paid internship - any age any background! Flexible schedule (175h or 350h projects) Read more: https://t.co/Jmjg6lygbM
0
6
20